Nikolic Marina, Lazarevic Nevena, Novakovic Jovana, Jeremic Nevena, Jakovljevic Vladimir, Zivkovic Vladimir, Bradic Jovana, Pecarski Danijela, Tel-Çayan Gülsen, Glamocija Jasmina, Sokovic Marina, Gregori Andrej, Petrovic Jovana
Department of Physiology, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovica 69, 34000 Kragujevac, Serbia.
Center of Excellence for Redox Balance Research in Cardiovascular and Metabolic Disorders, 34000 Kragujevac, Serbia.
Pharmaceuticals (Basel). 2023 May 25;16(6):787. doi: 10.3390/ph16060787.
The present study aimed to examine the biological activity and cardioprotective potential of heteropolysaccharides (TVH) in a rat model of metabolic syndrome (MetS). This study included 40 rats divided into 5 groups: CTRL-healthy non-treated rats; MetS-non-treated rats; and H-TV, M-TV and L-TV-rats with MetS treated with either 300, 200 or 100 mg/kg TVH per os for 4 weeks. After finishing the treatment, we conducted an oral glucose tolerance test (OGTT), hemodynamic measurements and the animals were sacrificed, hearts isolated and subjected to the Langendorff technique. Blood samples were used for the determination of oxidative stress parameters, lipid status and insulin levels. We showed that α-amylase inhibition was not the mode of TVH antidiabetic action, while TVH showed a moderate inhibition of pathogenic microorganisms' growth (MIC 8.00 mg·mL; MBC/MFC 16.00 mg·mL). H-TV and M-TV significantly reduced the level of prooxidants (O, HO, TBARS; < 0.05), increased antioxidants activity (SOD, CAT, GSH; < 0.05), reduced blood pressure ( < 0.05), improved glucose homeostasis in the OGTT test ( < 0.05), and ejection fraction ( < 0.05) and cardiac contractility ( < 0.05) compared to MetS ( < 0.05). Moreover, TVH treatment normalized the lipid status and decreased insulin levels compared to MetS rats ( < 0.05). The obtained results demonstrated that the TVH may be considered a useful agent for cardioprotection in MetS conditions.
本研究旨在检测杂多糖（TVH）在代谢综合征（MetS）大鼠模型中的生物活性和心脏保护潜力。本研究纳入40只大鼠，分为5组：CTRL组——健康未处理大鼠；MetS组——未处理的MetS大鼠；以及H-TV组、M-TV组和L-TV组——患有MetS的大鼠，分别口服300、200或100 mg/kg TVH，持续4周。治疗结束后，我们进行了口服葡萄糖耐量试验（OGTT）、血流动力学测量，然后处死动物，分离心脏并采用Langendorff技术处理。采集血样用于测定氧化应激参数、血脂状况和胰岛素水平。我们发现α-淀粉酶抑制并非TVH抗糖尿病作用的机制，而TVH对致病微生物的生长具有中度抑制作用（MIC 8.00 mg·mL；MBC/MFC 16.00 mg·mL）。与MetS组相比，H-TV组和M-TV组显著降低了促氧化剂水平（O、HO、TBARS；P<0.05），提高了抗氧化剂活性（SOD、CAT、GSH；P<0.05），降低了血压（P<0.05），在OGTT试验中改善了葡萄糖稳态（P<0.05），并提高了射血分数（P<0.05）和心脏收缩力（P<0.05）（P<0.05）。此外，与MetS大鼠相比，TVH治疗使血脂状况恢复正常并降低了胰岛素水平（P<0.05）。所得结果表明，在MetS情况下，TVH可被视为一种有用的心脏保护剂。
